Dr. Frederick P. Smith, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 53
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 828
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MD license D0033293
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medstar Georgetown University Hospital Washington, DC
- Sibley Memorial Hospital Washington, DC
Medical groups
- Suburban/nrh Medical Rehabilitation Inc (941 clinicians)
- Maryland Oncology Hematology PA (104 clinicians)
- Rcca MD LLC (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 828
- Services billed
- 352,976
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 43,500 | 25 |
| Injection, denosumab, 1 mg | 42,180 | 126 |
| Injection, pembrolizumab, 1 mg | 27,200 | 17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 4,203 | 45 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 3,780 | 21 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 2,486 | 605 |
| Insertion of needle into vein for collection of blood sample | 2,259 | 613 |
| Injection, fulvestrant, 25 mg | 1,940 | 13 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 1,880 | 12 |
| Injection, palonosetron hcl, 25 mcg | 1,661 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Chevy Chase, MD | 311 |
| Anastrozole Other prescribers in Chevy Chase, MD | 206 |
| Tamoxifen Citrate Other prescribers in Chevy Chase, MD | 84 |
| Ibrance (palbociclib) | 70 |
| Exemestane | 43 |
| Raloxifene Hcl Other prescribers in Chevy Chase, MD | 41 |
| Dexamethasone Other prescribers in Chevy Chase, MD | 40 |
| Famciclovir | 32 |
| Lorazepam Other prescribers in Chevy Chase, MD | 31 |
| Ondansetron Hcl Other prescribers in Chevy Chase, MD | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 49 companies reported 198 payments worth $7,754 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $2,105 |
|---|---|
| Novartis Pharmaceuticals Corporation | $1,596 |
| Janssen Biotech, Inc. | $334 |
| Merck Sharp & Dohme LLC | $278 |
| Pfizer Inc. | $230 |
| Array Biopharma Inc | $222 |
| Exelixis Inc. | $195 |
| Daiichi Sankyo Inc. | $179 |
| Food and Beverage | $4,927 |
|---|---|
| Consulting Fee | $1,640 |
| Long term medical supply or device loan | $1,164 |
| Education | $23.10 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Consulting Fee | $1,640 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| AstraZeneca Pharmaceuticals LP May 12, 2025 | Education in-kind Company’s descriptionJournal Article | $23.10 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| AstraZeneca Pharmaceuticals LP Jan 29, 2025 | Consulting Fee | $1,640 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $5,100 in research payments for these studies, mostly to the institutions running them.
- Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo Inc. · Completed · NCT04484142
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.